KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Operations (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cash from Operations for 15 consecutive years, with 19861000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 55.27% to 19861000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 47331000.0 through Dec 2025, down 72.47% year-over-year, with the annual reading at 47331000.0 for FY2025, 72.47% down from the prior year.
  • Cash from Operations for Q4 2025 was 19861000.0 at Supernus Pharmaceuticals, up from 61664000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 71119000.0 in Q2 2022, with the low at 61664000.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 28716000.0, with a median of 36037500.0 recorded in 2021.
  • The sharpest move saw Cash from Operations soared 1041.93% in 2023, then plummeted 215.22% in 2025.
  • Over 5 years, Cash from Operations stood at 48763000.0 in 2021, then crashed by 43.47% to 27564000.0 in 2022, then soared by 63.1% to 44958000.0 in 2023, then decreased by 1.23% to 44406000.0 in 2024, then crashed by 55.27% to 19861000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 19861000.0, 61664000.0, and 58535000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.